270 related articles for article (PubMed ID: 36386217)
1. The case for FAT10 as a novel target in fatty liver diseases.
Wimalarathne MM; Wilkerson-Vidal QC; Hunt EC; Love-Rutledge ST
Front Pharmacol; 2022; 13():972320. PubMed ID: 36386217
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-like protein FAT10: A potential cardioprotective factor and novel therapeutic target in cancer.
Zhang K; Chen L; Zhang Z; Cao J; He L; Li L
Clin Chim Acta; 2020 Nov; 510():802-811. PubMed ID: 32946796
[TBL] [Abstract][Full Text] [Related]
3. Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
Jia Y; French B; Tillman B; French S
Exp Mol Pathol; 2018 Aug; 105(1):144-149. PubMed ID: 30009772
[TBL] [Abstract][Full Text] [Related]
4. Human Leukocyte Antigen F Locus Adjacent Transcript 10 Overexpression Disturbs WISP1 Protein and mRNA Expression to Promote Hepatocellular Carcinoma Progression.
Yan J; Lei J; Chen L; Deng H; Dong D; Jin T; Liu X; Yuan R; Qiu Y; Ge J; Peng X; Shao J
Hepatology; 2018 Dec; 68(6):2268-2284. PubMed ID: 29790184
[TBL] [Abstract][Full Text] [Related]
5. Mitochondria, mitophagy, and the role of deubiquitinases as novel therapeutic targets in liver pathology.
Aryapour E; Kietzmann T
J Cell Biochem; 2022 Oct; 123(10):1634-1646. PubMed ID: 35924961
[TBL] [Abstract][Full Text] [Related]
6. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
7. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
9. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
10. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
11. The ubiquitin-like modifier FAT10 - much more than a proteasome-targeting signal.
Aichem A; Groettrup M
J Cell Sci; 2020 Jul; 133(14):. PubMed ID: 32719056
[TBL] [Abstract][Full Text] [Related]
12. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
Tillman EJ; Rolph T
Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
15. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
Brown E; Hydes T; Hamid A; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
[TBL] [Abstract][Full Text] [Related]
16. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
17. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.
Puengel T; Liu H; Guillot A; Heymann F; Tacke F; Peiseler M
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269812
[TBL] [Abstract][Full Text] [Related]
18. Role of necroptosis in chronic hepatic inflammation and fibrosis in a mouse model of increased oxidative stress.
Mohammed S; Nicklas EH; Thadathil N; Selvarani R; Royce GH; Kinter M; Richardson A; Deepa SS
Free Radic Biol Med; 2021 Feb; 164():315-328. PubMed ID: 33429022
[TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
20. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
